Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2011

Open Access 01-12-2011 | Research

Detection of DNA mismatch repair proteins in fresh human blood lymphocytes - towards a novel method for hereditary non-polyposis colorectal cancer (Lynch syndrome) screening

Authors: Samar Hassen, Bruce M Boman, Nawab Ali, Marcie Parker, Chandra Somerman, Zohra J Ali-Khan Catts, Akhtar A Ali, Jeremy Z Fields

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2011

Login to get access

Abstract

Background

A broad population-based assay to detect individuals with Lynch Syndrome (LS) before they develop cancer would save lives and healthcare dollars via cancer prevention. LS is caused by a germline mutation in a DNA mismatch repair (MMR) gene, especially protein truncation-causing mutations involving MSH2 or MLH1. We showed that immortalized lymphocytes from LS patients have reduced levels of full-length MLH1 or MSH2 proteins. Thus, it may be feasible to identify LS patients in a broad population-based assay by detecting reduced levels of MMR proteins in lymphocytes.

Methods

Accordingly, we determined whether MSH2 and MLH1 proteins can also be detected in fresh lymphocytes. A quantitative western blot assay was developed using two commercially available monoclonal antibodies that we showed are specific for detecting full-length MLH1 or MSH2. To directly determine the ratio of the levels of these MMR proteins, we used both antibodies in a multiplex-type western blot.

Results

MLH1 and MSH2 levels were often not detectable in fresh lymphocytes, but were readily detectable if fresh lymphocytes were first stimulated with PHA. In fresh lymphocytes from normal controls, the MMR ratio was ~1.0. In fresh lymphocytes from patients (N > 50) at elevated risk for LS, there was a bimodal distribution of MMR ratios (range: 0.3-1.0).

Conclusions

Finding that MMR protein levels can be measured in fresh lymphocytes, and given that cells with heterozygote MMR mutations have reduced levels of full-length MMR proteins, suggests that our immunoassay could be advanced to a quantitative test for screening populations at high risk for LS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics. Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.CrossRef Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics. Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.CrossRef
2.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer Statistics. Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.CrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer Statistics. Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.CrossRef
3.
go back to reference Niessen RC, Berends MJW, Wu Y, Sijmons RH, Hollema H, Ligtenberg MJL, deWalle HEK, de Vries EGE, Karrenbeld A, Buys CHCM, van der Zee AGJ, Hofstra RMW, Kleibeuker JH: Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer. Gut. 2006, 55: 1781-1788. 10.1136/gut.2005.090159.PubMedCentralCrossRefPubMed Niessen RC, Berends MJW, Wu Y, Sijmons RH, Hollema H, Ligtenberg MJL, deWalle HEK, de Vries EGE, Karrenbeld A, Buys CHCM, van der Zee AGJ, Hofstra RMW, Kleibeuker JH: Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer. Gut. 2006, 55: 1781-1788. 10.1136/gut.2005.090159.PubMedCentralCrossRefPubMed
4.
go back to reference Liya G, Hong Y, McCulloch S, Watanabe H, Li G-M: ATP-dependent interaction of human mismatch repair proteins and dual role of PCNA in mismatch repair. Nucleic Acids Research. 1998, 26: 1173-1178. 10.1093/nar/26.5.1173.CrossRef Liya G, Hong Y, McCulloch S, Watanabe H, Li G-M: ATP-dependent interaction of human mismatch repair proteins and dual role of PCNA in mismatch repair. Nucleic Acids Research. 1998, 26: 1173-1178. 10.1093/nar/26.5.1173.CrossRef
5.
go back to reference Yamasaki Y, Matsushima M, Tanaka H, Tajiri S, Fukuda R, Ozawa H, Takagi A, Hirabayashi K, Sadahiro S: Patient with Eight Metachronous Gastrointestinal Cancers Thought to be Hereditary Nonpolyposis Colorectal Cancer (HNPCC). Inter Med. 2010, 49: 209-213. 10.2169/internalmedicine.49.2316.CrossRef Yamasaki Y, Matsushima M, Tanaka H, Tajiri S, Fukuda R, Ozawa H, Takagi A, Hirabayashi K, Sadahiro S: Patient with Eight Metachronous Gastrointestinal Cancers Thought to be Hereditary Nonpolyposis Colorectal Cancer (HNPCC). Inter Med. 2010, 49: 209-213. 10.2169/internalmedicine.49.2316.CrossRef
6.
go back to reference Learn PA, Kahlenberg MS: Hereditary Colorectal Cancer Syndromes and the Role of the Surgical Oncologist. Surg Oncol Clin N Am. 2008, 18: 121-144.CrossRef Learn PA, Kahlenberg MS: Hereditary Colorectal Cancer Syndromes and the Role of the Surgical Oncologist. Surg Oncol Clin N Am. 2008, 18: 121-144.CrossRef
7.
go back to reference Fields JZ, Gao Z, Gao Z, Lewis M, Maimonis P, Harvey J, Lynch HT, Boman BM: Immunoassay for wild-type protein in lymphocytes predicts germline mutations in patients at risk for hereditary colorectal cancer. The Journal of Laboratory and Clinical Medicine. 2004, 143: 59-66. 10.1016/j.lab.2003.10.001.CrossRefPubMed Fields JZ, Gao Z, Gao Z, Lewis M, Maimonis P, Harvey J, Lynch HT, Boman BM: Immunoassay for wild-type protein in lymphocytes predicts germline mutations in patients at risk for hereditary colorectal cancer. The Journal of Laboratory and Clinical Medicine. 2004, 143: 59-66. 10.1016/j.lab.2003.10.001.CrossRefPubMed
8.
go back to reference Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.CrossRefPubMed Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.CrossRefPubMed
9.
go back to reference Agarwal R, Mumtaz H, Ali N: Role of inositol polyphosphates in programmed cell death. Mol Cell Biochem. 2009, 328: 155-165. 10.1007/s11010-009-0085-6.CrossRefPubMed Agarwal R, Mumtaz H, Ali N: Role of inositol polyphosphates in programmed cell death. Mol Cell Biochem. 2009, 328: 155-165. 10.1007/s11010-009-0085-6.CrossRefPubMed
10.
go back to reference Parsons R, Li GM, Longley M, Modrich P, Liu B, Berk T, Hamilton SR, Kinzler KW, Vogelstein B: Mismatch repair deficiency in phenotypically normal human cells. Science. 1995, 268: 738-740. 10.1126/science.7632227.CrossRefPubMed Parsons R, Li GM, Longley M, Modrich P, Liu B, Berk T, Hamilton SR, Kinzler KW, Vogelstein B: Mismatch repair deficiency in phenotypically normal human cells. Science. 1995, 268: 738-740. 10.1126/science.7632227.CrossRefPubMed
11.
go back to reference Coolbaugh-Murphy M, Xu JP, Ramagli LS, Ramagli BC, Brown BW, Lynch PM, Hamilton SR, Frazier L, Siciliano MJ: Microsatellite instability in the peripheral blood leukocytes of HNPCC patients. Human Mutation. 2010, 31: 317-324. 10.1002/humu.21190.PubMedCentralCrossRefPubMed Coolbaugh-Murphy M, Xu JP, Ramagli LS, Ramagli BC, Brown BW, Lynch PM, Hamilton SR, Frazier L, Siciliano MJ: Microsatellite instability in the peripheral blood leukocytes of HNPCC patients. Human Mutation. 2010, 31: 317-324. 10.1002/humu.21190.PubMedCentralCrossRefPubMed
12.
go back to reference Marra G, D'Atri S, Corti C, Bonmassar L, Cattaruzza MS, Schweizer P, Heinimann K, Bartosova Z, Nystrom-Lahti M, Jiricny J: Tolerance of human MSH21/2 lymphoblastoid cells to the methylating agent temozolomide. Proc Natl Acad Sci USA. 2001, 98: 7164-7169. 10.1073/pnas.121136498.PubMedCentralCrossRefPubMed Marra G, D'Atri S, Corti C, Bonmassar L, Cattaruzza MS, Schweizer P, Heinimann K, Bartosova Z, Nystrom-Lahti M, Jiricny J: Tolerance of human MSH21/2 lymphoblastoid cells to the methylating agent temozolomide. Proc Natl Acad Sci USA. 2001, 98: 7164-7169. 10.1073/pnas.121136498.PubMedCentralCrossRefPubMed
13.
go back to reference Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008, 26: 5783-8. 10.1200/JCO.2008.17.5950.PubMedCentralCrossRefPubMed Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008, 26: 5783-8. 10.1200/JCO.2008.17.5950.PubMedCentralCrossRefPubMed
Metadata
Title
Detection of DNA mismatch repair proteins in fresh human blood lymphocytes - towards a novel method for hereditary non-polyposis colorectal cancer (Lynch syndrome) screening
Authors
Samar Hassen
Bruce M Boman
Nawab Ali
Marcie Parker
Chandra Somerman
Zohra J Ali-Khan Catts
Akhtar A Ali
Jeremy Z Fields
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2011
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-30-100

Other articles of this Issue 1/2011

Journal of Experimental & Clinical Cancer Research 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine